Navigation Links
For many prostate cancer patients, Web sites are too difficult to read
Date:10/29/2012

MAYWOOD, IL - Ninety million American adults read below high school levels, so the National Institutes of Health recommends that patient-education materials be written at the fourth-through-six grade level.

But a Loyola University Medical Center study has found that only 4.8 percent of web sites describing prostate cancer were written below a high school reading level. The median reading level was 12th grade.

"This is probablematic for one-third of Americans who seek to further educate themselves using online resources," senior author Gopal Gupta, MD and colleagues wrote. The study is published online ahead of print in the Journal of Urology.

Gupta and colleagues identified 62 web sites by searching for "prostate cancer" "prostate cancer treatment" and "prostatectomy" on Google, Yahoo and Bing search engines. Researchers used word processing software to test the readability of the first 300 words of each web site.

To assess readability, researchers used the Flesch-Kincaid test, which measures the reading grade level, and the Flesch reading ease test, which assigns a readability score of 0 to 100. The tests are based on formulas that incorporate total number of words, sentences and syllables.

Sixty-three percent of the sites were written above a 12th grade reading level, and the median Flesch reading ease score for all sites a relatively difficult 38.1. (The Flesch reading ease score ranges from 0 to 100. A web site with a score of 90 to 100 would be easily understood by an 11-year-old; a score of 60-to-70 would be understood by 13-to-15-year-olds; and scores lower than 30 would be suited to college grads.)

Web sites with the easiest readability scores were News-Medical Net (8th grade level), Consumer Reports.org (8.9), Family Doctor.org (8.95), UPMC Cancer Centers (9.2) and NIH Pubmed Health (9.8).

"It was discouraging to find that only 4.8 percent of these sites had information written for those below a high school reading level," Gupta and colleagues wrote. "No sites in our study were written at the level recommended by the NIH (4-6th grade). Given that nearly one-third of the U.S. population reads below high school level, this raises the concern that many patients will have difficulty comprehending online information about prostate cancer treatment options."

Prostate cancer is among the more difficult topics for patients to comprehend. There are at least four options (surgery, radiation beam therapy, radiation seeds and active surveillance). Each option has pros and cons, which vary according to the patient's age, tumor type, overall health, etc. Doctors may find it difficult to simplify technology-based treatments, anatomical descriptions and medical terminology. And some terms doctors take for granted, such as "erection" and "impotent," might not be understood by patients with low health literacy.

Researchers concluded: "Clinicians should be aware that some of their patients may not be able to read online information and should consciously guide patients with low literacy to not only high-quality web sites, but also sites that are easy-to-read, to prevent confusion and anxiety after being diagnosed with prostate cancer."

Dr. Gupta is an instructor in the Departments of Urology and Surgery and the Oncology Institute of Loyola University Chicago Stritch School of Medicine. His special interests include urologic oncology and robotic and minimally invasive surgery.

Co-authors are of the readability study are Chandy Ellimoottil, MD, (first author); Anthony Polcari, MD; and Adam Kadlec, MD.


'/>"/>
Contact: Jim Ritter
jritter@lumc.edu
708-216-2445
Loyola University Health System
Source:Eurekalert

Related medicine news :

1. Viagra Can Help Prostate Cancer Patients Maintain Sex Lives: Study
2. Drop in testosterone tied to prostate cancer recurrence
3. Moffitt Researchers find genetic predictors of fatigue for some prostate cancer patients
4. First web-based prostate cancer database launches
5. Lab Contamination Behind Debunked Link Between Virus, Prostate Cancer
6. Researchers reveal underlying mechanism of powerful chemotherapy for prostate cancer treatment
7. Cloned receptor paves way for new breast and prostate cancer treatment
8. Drug Used to Prevent Prostate Cancer Wont Lower Quality of Life
9. Taking Breaks From Prostate Cancer Hormone Therapy Seems Safe: Study
10. Norwich Research Park Prostate Cancer Initiative wins major award
11. FDA OKs Drug for Advanced Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... IN (PRWEB) , ... February 10, 2016 , ... ... benefits advisory organization, welcomes S.S. Nesbitt as the latest addition to its growing ... has seven other locations throughout the Southeast, from Orlando to Huntsville and in ...
(Date:2/10/2016)... ... ... Armune BioScience signed a definitive agreement with ARCpoint Labs ... the country. Launched in April of 2015, Apifiny is the only cancer specific, non-PSA ... volume exceeded 3,000 tests in 2015. Primary care physicians and urologists have utilized Apifiny ...
(Date:2/10/2016)... ... February 10, 2016 , ... For additional information contact ... , Pioneering book "Better with Age: The Ultimate Guide to Brain Training" by award-winning ... improve memory. The book’s publication date is March 16, 2016. A free review ...
(Date:2/10/2016)... ... February 10, 2016 , ... Everseat has joined the award-winning ... to physicians. The integration will enable Allscripts users to post open appointments to ... mobile app. , The partnership gives Everseat substantial added power to help Allscripts ...
(Date:2/10/2016)... ... ... Workrite Ergonomics this week announced the launch of the Conform Monitor Arm Series, ... was to develop a product from the ground up that would provide the most ... Hulsey, Product Manager for Workrite Ergonomics. “The Conform series features a wide variety ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... -- LexisNexis® Risk Solutions, a leading provider of data, ... LexisNexis Provider Performance Monitor , a clinical ... the quality and efficiency of provider networks through ... measuring provider performance through Provider Performance Monitor, payers ... improve the patient experience and reduce costs, as ...
(Date:2/10/2016)... SAN DIEGO , Feb. 10, 2016 ... biopharmaceutical company developing novel, clinical-stage therapies for sickle cell ... an underwritten public offering of 29,090,910 units at a ... unit consists of one share of the Company,s common ... the Company,s common stock at an exercise price of ...
(Date:2/10/2016)... ALSP, Inc. announced that it has appointed Col.(Retired) Dallas ... preparation for its move into clinical trials with its lead ... are pleased to welcome Dallas Hack onto the ... of such practical knowledge and far-reaching experience in Traumatic Brain ... broad experience and success as a clinician and researcher in ...
Breaking Medicine Technology: